Why a Genomic Test Like the Oncotype DX Genomic Prostate Score® (GPS) test?

Clinical features alone may not show the whole picture

Biopsy alone does not always accurately differentiate candidates for active surveillance.

GG = Grade group; GS = Gleason Score; RP = radical prostatectomy

~1 in 4 patients with a GS 6 at biopsy had more aggressive disease (GS >=7) at surgery1

~1 in 5 patients with a GS 7 at biopsy had less aggressive disease (GS 6) at surgery1

Biopsies often do not accurately categorize risk because of tumor heterogeneity, multifocality, and undersampling in prostate cancer.2

More accurate measures of tumor aggressiveness lead to more treatment decisions.


Genetic tests screen for inherited risk factors or spontaneously arising mutations. They can help identify the risk of getting cancer or how a tumor may respond to certain therapies.3

Genomic tests examine gene expression levels within a sample of tumor tissue. They provide information about the tumor’s biology and aggressiveness.3

What elevates the GPS™ test above other tests?

Tissue-based genomic assays vary in their validation data to predict long-term and short-term outcomes. They also differ in the ability of their results to help guide the active surveillance decision in low-risk and favorable intermediate-risk patients.

The only assay designed for critical treatment decisions in clinically low-risk, early-stage prostate cancer

Bring together biology, validation, and endpoint insights to soar above the competition:

*Studies performed in biopsy samples from clinically low risk and/or AS-candidate patient cohorts
**GPS Validation Studies

  1. Foxman B, et al. The Epidemiology of Urinary Tract Infection. Nat Rev Urol 2010; 7: 653-60.
  2. Flores-Mireles AL, et al. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. Rev Microbiol 2015; 13: 269-84.
  3. Sathiananthamoorthy S, Malone-Lee J, Gill K, et al. Reassessment of Routine Midstream Culture in Diagnosis of Urinary Tract Infection. J Clin Microbiol. 2019;57(3):e01452-18. Published 2019 Feb 27. doi:10.1128/JCM.01452-18.
  4. Annemarie D, David B, Kelly R, Natalie L, Meghan C, et al. Utilization of M-PCR and P-AST for Diagnosis and Management of Urinary Tract Infections in Home-Based Primary Care. JOJ Urology & Nephrology, 2020; 7(2): 555707. DOI: 10.19080/JOJUN.2020.07.555707